1.1 	A House concurrent resolution
1.2 	designating May 1 to 7, 2023, as Tardive Dyskinesia Awareness Week.
1.3 	WHEREAS, many people with serious mental health conditions, such as bipolar disorder, 
1.4 	major depression, schizophrenia, and schizoaffective disorder, or gastrointestinal disorders, including 
1.5 	gastroparesis, nausea, and vomiting, may be treated with medications that work as dopamine receptor 
1.6 	blocking agents (DRBAs), including antipsychotics; and
1.7 	WHEREAS, while ongoing treatment with these medications can be necessary, prolonged 
1.8 	use can also lead to tardive dyskinesia (TD), an involuntary movement disorder that is characterized 
1.9 	by uncontrollable, abnormal, and repetitive movements of the face, torso, or other body parts; and
1.10 	WHEREAS, it is estimated that TD affects approximately 600,000 people in the United 
1.11 	States, and approximately 70 percent of people with TD have not been diagnosed, making it important 
1.12 	to raise awareness about the symptoms and impact of TD because even mild symptoms of TD can 
1.13 	have physical, social, and emotional consequences; and
1.14 	WHEREAS, it is important that people taking DRBAs be monitored for TD, as regular 
1.15 	screening for TD in these patients is recommended by the American Psychiatric Association; and
1.16 	WHEREAS, clinical research has led to the availability of two treatments for adults with TD 
1.17 	by the United States Food and Drug Administration; and
1.18 	WHEREAS, the Minnesota Legislature can raise awareness of tardive dyskinesia in the public 
1.19 	and medical community; NOW, THEREFORE,
1.20 	BE IT RESOLVED by the House of Representatives of the State of Minnesota, the Senate 
1.21 	concurring, that it designates May 1 to 7, 2023, as Tardive Dyskinesia Awareness Week and 
1.22 	encourages each individual in the state of Minnesota to become better informed about and aware 
1.23 	of tardive dyskinesia.